180 related articles for article (PubMed ID: 18358073)
1. ODN 491, a novel antisense oligodeoxynucleotide that targets thymidylate synthase, exerts cell-specific effects in human tumor cell lines.
Jason TL; Figueredo R; Ferguson PJ; Vincent MD; Berg RW; Koropatnick J
DNA Cell Biol; 2008 May; 27(5):229-40. PubMed ID: 18358073
[TBL] [Abstract][Full Text] [Related]
2. Tumor growth inhibition in vivo and G2/M cell cycle arrest induced by antisense oligodeoxynucleotide targeting thymidylate synthase.
Berg RW; Werner M; Ferguson PJ; Postenka C; Vincent M; Koropatnick DJ; Behrend E
J Pharmacol Exp Ther; 2001 Aug; 298(2):477-84. PubMed ID: 11454908
[TBL] [Abstract][Full Text] [Related]
3. Antisense targeting of thymidylate synthase (TS) mRNA increases TS gene transcription and TS protein: effects on human tumor cell sensitivity to TS enzyme-inhibiting drugs.
Jason TL; Berg RW; Vincent MD; Koropatnick J
Gene Expr; 2007; 13(4-5):227-39. PubMed ID: 17605297
[TBL] [Abstract][Full Text] [Related]
4. Antisense down-regulation of thymidylate synthase to suppress growth and enhance cytotoxicity of 5-FUdR, 5-FU and Tomudex in HeLa cells.
Ferguson PJ; Collins O; Dean NM; DeMoor J; Li CS; Vincent MD; Koropatnick J
Br J Pharmacol; 1999 Aug; 127(8):1777-86. PubMed ID: 10482907
[TBL] [Abstract][Full Text] [Related]
5. A "combination oligonucleotide" antisense strategy to downregulate thymidylate synthase and decrease tumor cell growth and drug resistance.
Berg RW; Ferguson PJ; Vincent MD; Koropatnick DJ
Cancer Gene Ther; 2003 Apr; 10(4):278-86. PubMed ID: 12679800
[TBL] [Abstract][Full Text] [Related]
6. The means to an end of tumor cell resistance to chemotherapeutic drugs targeting thymidylate synthase: shoot the messenger.
Berg RW; Ferguso PJ; DeMoor JM; Vincen MD; Koropatnick J
Curr Drug Targets; 2002 Aug; 3(4):297-309. PubMed ID: 12102601
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic potential of antisense oligodeoxynucleotides to down-regulate thymidylate synthase in mesothelioma.
Flynn J; Berg RW; Wong T; van Aken M; Vincent MD; Fukushima M; Koropatnick J
Mol Cancer Ther; 2006 Jun; 5(6):1423-33. PubMed ID: 16818500
[TBL] [Abstract][Full Text] [Related]
8. Antisense nucleic acids targeted to the thymidylate synthase (TS) mRNA translation start site stimulate TS gene transcription.
DeMoor JM; Vincent MD; Collins OM; Koropatnick J
Exp Cell Res; 1998 Aug; 243(1):11-21. PubMed ID: 9716444
[TBL] [Abstract][Full Text] [Related]
9. Antisense-induced down-regulation of thymidylate synthase and enhanced cytotoxicity of 5-FUdR in 5-FUdR-resistant HeLa cells.
Ferguson PJ; DeMoor JM; Vincent MD; Koropatnick J
Br J Pharmacol; 2001 Dec; 134(7):1437-46. PubMed ID: 11724749
[TBL] [Abstract][Full Text] [Related]
10. Combination silencer RNA (siRNA) targeting Bcl-2 antagonizes siRNA against thymidylate synthase in human tumor cell lines.
Pandyra AA; Berg R; Vincent M; Koropatnick J
J Pharmacol Exp Ther; 2007 Jul; 322(1):123-32. PubMed ID: 17452420
[TBL] [Abstract][Full Text] [Related]
11. Induction of apoptosis in small-cell lung cancer cells by an antisense oligodeoxynucleotide targeting the Bcl-2 coding sequence.
Ziegler A; Luedke GH; Fabbro D; Altmann KH; Stahel RA; Zangemeister-Wittke U
J Natl Cancer Inst; 1997 Jul; 89(14):1027-36. PubMed ID: 9230884
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of thymidylate synthase activity by antisense oligodeoxynucleotide and possible role in thymineless treatment.
Lin SB; Ts'o PO; Sun SK; Choo KB; Yang FY; Lim YP; Tsai HL; Au LC
Mol Pharmacol; 2001 Sep; 60(3):474-9. PubMed ID: 11502877
[TBL] [Abstract][Full Text] [Related]
13. Combining small interfering RNAs targeting thymidylate synthase and thymidine kinase 1 or 2 sensitizes human tumor cells to 5-fluorodeoxyuridine and pemetrexed.
Di Cresce C; Figueredo R; Ferguson PJ; Vincent MD; Koropatnick J
J Pharmacol Exp Ther; 2011 Sep; 338(3):952-63. PubMed ID: 21673071
[TBL] [Abstract][Full Text] [Related]
14. Antisense oligonucleotides targeting XIAP induce apoptosis and enhance chemotherapeutic activity against human lung cancer cells in vitro and in vivo.
Hu Y; Cherton-Horvat G; Dragowska V; Baird S; Korneluk RG; Durkin JP; Mayer LD; LaCasse EC
Clin Cancer Res; 2003 Jul; 9(7):2826-36. PubMed ID: 12855663
[TBL] [Abstract][Full Text] [Related]
15. Desensitization and sensitization of cells to fluoropyrimidines with different antisenses directed against thymidylate synthase messenger RNA.
Ju J; Kane SE; Lenz HJ; Danenberg KD; Chu E; Danenberg PV
Clin Cancer Res; 1998 Sep; 4(9):2229-36. PubMed ID: 9748143
[TBL] [Abstract][Full Text] [Related]
16. Cationic lipids reduce time and dose of c-myc antisense oligodeoxynucleotides required to specifically inhibit Burkitt's lymphoma cell growth.
Williams SA; Chang L; Buzby JS; Suen Y; Cairo MS
Leukemia; 1996 Dec; 10(12):1980-9. PubMed ID: 8946941
[TBL] [Abstract][Full Text] [Related]
17. Antitumor effect of c-myc antisense phosphorothioate oligodeoxynucleotides on human melanoma cells in vitro and and in mice.
Leonetti C; D'Agnano I; Lozupone F; Valentini A; Geiser T; Zon G; Calabretta B; Citro G C; Zupi G
J Natl Cancer Inst; 1996 Apr; 88(7):419-29. PubMed ID: 8618233
[TBL] [Abstract][Full Text] [Related]
18. 2'-O-methyl-modified phosphorothioate antisense oligonucleotides have reduced non-specific effects in vitro.
Yoo BH; Bochkareva E; Bochkarev A; Mou TC; Gray DM
Nucleic Acids Res; 2004; 32(6):2008-16. PubMed ID: 15064360
[TBL] [Abstract][Full Text] [Related]
19. Antisense-mediated hTERT inhibition specifically reduces the growth of human bladder cancer cells.
Kraemer K; Fuessel S; Schmidt U; Kotzsch M; Schwenzer B; Wirth MP; Meye A
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3794-800. PubMed ID: 14506173
[TBL] [Abstract][Full Text] [Related]
20. c-myc antisense oligodeoxynucleotides enhance the efficacy of cisplatin in melanoma chemotherapy in vitro and in nude mice.
Citro G; D'Agnano I; Leonetti C; Perini R; Bucci B; Zon G; Calabretta B; Zupi G
Cancer Res; 1998 Jan; 58(2):283-9. PubMed ID: 9443406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
